SP-26

About Silo Pharma

Silo Pharma is a Nasdaq-listed biotech focused on developing novel therapeutics for central nervous system disorders and chronic pain through a capital-efficient licensing and development model. Its core strategy involves in-licensing promising candidates from academic partners and advancing them via the FDA's 505(b)(2) regulatory pathway to reduce time and cost. Key assets include SPC-15, a prophylactic intranasal treatment for stress-induced disorders, and SP-26, a ketamine-based implant for fibromyalgia. The company aims to address significant unmet medical needs in large, growing markets with limited treatment options.

Therapeutic Areas